Oksana Mokliatchouk

Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

Ralf Gold, Douglas L. Arnold, Amit Bar‐Or et al. · Multiple Sclerosis Journal · 2021 · 75 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +16

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Derek J. Jonker, Lee S. Rosen, Michael B. Sawyer et al. · Annals of Oncology · 2010 · 72 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis

Patrick Vermersch, Matthew Scaramozza, Seth Levin et al. · JAMA Network Open · 2022 · 53 citations · Full text

Medicine, Neurology, Pediatrics +14

Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry

Kerstin Hellwig, David Rog, Christopher McGuigan et al. · Neurology Neuroimmunology & Neuroinflammation · 2021 · 31 citations · Full text

Medicine, Maternal Health, Obstetrics +17

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

Christopher R. Garrett, Lillian L. Siu, Anthony B. El-Khoueiry et al. · British Journal of Cancer · 2011 · 29 citations · Full text

Medicine, Oncology, Pharmacology +17